Phase II, multi-centered, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety of recombinant human Epidermal Growth Factor (rhEGF) at a dose of 25 or 75 micrograms intralesionally 3 times a week for up to 12 weeks, in patients with diabetic foot ulcer (Wagner grade 1 or 2).

Trial Profile

Phase II, multi-centered, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety of recombinant human Epidermal Growth Factor (rhEGF) at a dose of 25 or 75 micrograms intralesionally 3 times a week for up to 12 weeks, in patients with diabetic foot ulcer (Wagner grade 1 or 2).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Recombinant epidermal growth factor (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Sponsors Praxis Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record.
    • 13 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top